Cloudbreak Pharma Inc. (Ticker: 2592 HK) is a Hong Kong-based, clinical-stage ophthalmology biotechnology company focusing on the development of treatments for eye diseases. Cloudbreak Pharma plans to list on the Hong Kong Stock Exchange on July 3, 2025, offering 60.58 million shares at HKD 10.10 to raise HKD 611.88 million (approximately $77.95 million). The company's market capitalization at the time of the offer is reportedly $1.08 billion. According to company documents, proceeds from the offering will likely be used to fund the ongoing clinical trials for its core products, CBT-001 for pterygium and CBT-009 for juvenile myopia, and to advance its pipeline of other clinical and pre-clinical drug candidates.